Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GBB101
- Development stage
- Preclinical
- Lead developer
- Great Bay Bio
- Administration
- Subcutaneous, Intravenous
01
Overview
GBB101 is a long-acting biologic drug candidate being developed as an innovative injectable therapy for anemia associated with renal dysfunction. It is being jointly developed by Great Bay Bio and Boji Medical, which have formed a strategic collaboration to advance this long-acting anti-anemia biologic into clinical development for patients with chronic kidney disease–related anemia who require improved hemoglobin control and reduced dosing frequency.[12][14] While specific target and molecular details have not been publicly disclosed, GBB101 is positioned as a next-generation erythropoiesis-stimulating therapy designed to improve anemia symptoms in this population.[12][14]
Beyond the preview
Go deeper on GBB101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GBB101.